Ahead of Cannabis Europa London 2022, BusinessCann spoke to the organization’s managing director Lorenza Romanese about the current state of European hemp, and what needs to be done for its evolution to continue. BC: Thanks for joining us Lorenza, could you start by telling us a bit about yourself and the work you do over at the EIHA. My name is Lorenza Romanese, I’m the managing director of the EIHA. We are a small team of five based here in Brussels, and we represent and defend the three main actors along the supply chain of hemp, the producers, the manufacturers and processing companies, and the traders. We are a company-driven association, meaning that companies pay a membership fee to enjoy benefits, including receiving industry updates on a regular basis. They get the information from us, and our members are our source of information. We aim to grasp information from the sector and translate it into policy messages and try to solve the problems of the companies on the market. We also collect information from the main DGs (Directorate-Generals for the European Commission), which is like the ministry for the rest of the member states. This is what we do. BC: Last month saw the publication of the UK FSA’s Novel Foods Public List, you must have been pleased to see a number of the EIHA consortium members included? The EIHA is very, very happy about the publication of the list. Of course, we regret the delay, we were waiting for the list for one year. But we definitely welcome the publication, we are very happy that both our applications are now displayed on their on-hold list. Let’s recall that the on-hold list is for the companies and applications that still have some toxicological studies going on, as in our case. Once the toxicological studies are concluded, then we will upload the report to support the safety of our products into the FSA portal. Then we should be able to move to the validated list. Surely the on-hold list and the validated list gives the possibility to operate and stay on the market. The safety evaluation of these products will be done, as will the risk assessment, at a later stage within the FSA as well as with EFSA in Europe. So today it’s more about administration and the willingness to invest in toxicological studies, and then the risk assessment will come later. BC: You mentioned in a press release ‘inaccuracies, inconsistencies and indeed a few surprising absences on the list’, can you explain what you meant here? Let me underline again, that we really welcome the approach and the willingness from FSA to regulate this market. Probably all of us, even us as a trade association, underestimated the size of the market. Nevertheless, the project was very, very ambitious. The FSA has decided to control, check and display the brands, and by displaying the brands, they have multiplied the number of products and the collection of data that was needed to come up with this list. Therefore, it’s more than human to have some mistakes. 10 days after the publication of our press release, we are very pleased that all the mistakes were corrected and all our members are now displayed on the list, with one pending. We are still waiting on some clarifications on documentation to be submitted to show that the last member was compliant. BC: Can you walk us through your toxicological studies? We’re jumping into a big project that goes beyond the usual public affairs work we are doing here. We understood that the sector was facing a common challenge that was very complex, very costly, very ambitious. Therefore, we have decided to join forces and to prepare a common reply to this challenge. So we have built this specification, we decided which were the products that they want to trade in the UK and European market, and once we have agreed on the specification we did a simple assessment of how many studies were already available for these products. We noticed some gaps and decided to collect €3.5m to invest into toxicological studies, which have been divided into three main costs. The first are toxicological studies dedicated to isolate CBD, so all studies necessary to ensure the safety of this product and to define the correct TDI (Tolerable Daily Intake). We have done the same toxicological package with a little more complexity for full spectrum extracts, and the third main expense has been conducting the biggest clinical trials for THC. The scope of this clinical trial is to make sure that we might be able to increase the level and the accurate reference dose for THC. There are many things that we need to clarify, we need to define a NOAEL (No Observed Adverse Effect Level), an appropriate LOAEL (Lowest Observed Adverse Effect Level), and an appropriate uncertainty factor measurement for THC. When it comes to CBD, there are gaps here as well. So we need to define a correct TDI. The FSA guidelines propose a 7mg TDI, we would like to increase this. The level of THC and other minor cannabinoids in full spectrum extracts is another. We’re aiming to define the values that are still missing and to identify higher values than the ones that have been proposed by the authorities. BC: Can you give us an update on your preliminary findings and when you think they’ll be completed? Toxicology studies are a complex package of studies, some are shorter, some are long, some must be conducted in parallel, others are consequential. The most important are 90-day studies. These give us the possibility to monitor the rats for a long period, followed by a recovery period, so we can measure the parameters in vivo, then measure things like toxicity in the liver. When it comes to isolate CBD, the 90 day studies have been completed. We are now drafting the report to be submitted to the FSA, so I expect the submission on this at the latest July this year. When it comes to full spectrum, the results will come by the end of the year, when it comes to THC on human beings, the results will come in 2023. So all the studies both for isolate and full spectrum CBD are concluded. And so far, I can simply say that there is nothing to worry about. There were no values beyond or even near to the limit. So this product, according to the level that we have tested, can be considered safe. When what we have been seeing is that all the text tests were negative, which in toxicology is very good because it means that there is no adverse effect for the parameters that we have been testing at the level that we have been testing. BC: The European Commission recently announced a decision to establish a new maximum level of THC in hemp food products, what does this mean for the EU’s hemp industry? The EIHA have been advocating for a common approach when it comes to a maximum level of THC in food, so we welcome the new regulation coming from Europe that will be directly applicable in all member states. Until a few weeks ago in Europe, there was no maximum level there were no regulation, no provision, there were only a guidelines drafted by EFSA. This is a huge achievement for the sector, because finally from Lisbon to Warsaw, all products will be will be the same because all the limits will finally be European limits. There are still some more points that might be clarified. But let’s wait for our toxicological studies on THC that might support further changes later on. BC: During the controversial Kanavape case in 2020, which threatened to class CBD as a narcotic across Europe, it was suggested that this galvanised support for a rise in THC limits across the sector. Do you think this has had an impact on recent developments? The court case arrived in the most needed moment for the sector. Let’s do a small recap. In 1997 the European Commission said that hemp extract leaves and flowers were not a novel food, leading to lots of investment in the sector. In 2016 certain products containing cannabinoids were considered novel foods for the first time, but basically low concentration products were still sellable as food. In 2019 all products were considered a novell food. In 2020, hemp was considered a narcotic. And then came the Kanavape court case, as I said it arrived in the in a good moment for the sector. The Judge of the Court of Justice clearly clarified that hemp should not be regarded as a narcotic, and all parts of the plants should be marketable as none of them should be considered a narcotic. It was a game changer from this point of view. We cannot measure a real impact today, because when it comes to cannabis, it always takes a little bit of time. Since the adoption of the ruling 2020, we have not seen any major change in Europe. I know that the European Commission is still working on integrating this principle within the EU. So again, let’s wait for the results of our toxicological studies. The post Lorenza Romanese: Worlds Largest THC Toxicological Study Shows ‘Very Positive’ Signs appeared first on ilesol. from ilesol https://ilesol.com/lorenza-romanese-worlds-largest-thc-toxicological-study-shows-very-positive-signs/ Via https://mairapostema.tumblr.com/post/681421446947422208
0 Comments
5 Ways to Use CBD for Anxiety by Sponsored In recent years, many people have started using CBD as a remedy to various health issues thanks to its anti-inflammatory, analgesic, and sedative properties. One of the most prominent uses of CBD is anxiety treatment – cannabidiol interacts with brain receptors altering serotonin inhibition, which results in reduced anxiety and improved sleep and mood. Other anxiety treatments commonly come in the form of pills or medication, but CBD, due to its nature, can be ingested in multiple ways, with each method providing different benefits. CBD is usually taken in the form of oil, and it’s easy to see why. It can be ingested, added to food or applied topically. However, the cannabidiol market is still developing, and it’s not uncommon to find CBD in various other forms, such as tinctures, edibles, topical creams and even vape liquids. Below, you will find the five most common ways of consuming CBD for anxiety. Read on to find out which one is the best for you! Vaping CBD OilVaping has become a popular way of consuming nicotine in recent years, and it’s not uncommon to find people using vape pens for CBD oil as well. Vaping CBD has a few advantages over other methods. First of all, it’s one of the fastest ways to feel the effects of cannabidiol. When CBD is inhaled, it enters the bloodstream through the lungs and bypasses the digestive system, taking effect almost immediately. Vaping is also an excellent option for people who don’t like the taste of CBD oil. CBD vape liquids come in a variety of flavors, so you can easily find one that suits your taste. Apart from that, vaping is a convenient way to take CBD on the go – all you need is your bottle of CBD vape juice and a vape pen – any device will do, whether it’s a disposable one or a more advanced mod like those available on vapekit.co.uk. Taking CBD Oil SublinguallyTaking cannabidiol oil sublingually, or in other words, by placing a few drops under your tongue and keeping them there for a minute or two before swallowing, is a more traditional way of consuming CBD. It’s also one of the most effective, as it allows CBD to be absorbed directly into the bloodstream through the mucous membranes in your mouth, skipping the digestive system altogether. Just like with vaping, the effects of taking CBD oil sublingually are almost immediate. However, they also last longer – up to 6 hours. This method is perfect for people who need long-lasting relief from anxiety or other conditions. CBD sprays are a great option for those who want to take cannabidiol sublingually in a discreet manner. All you need to do is spray a few times under your tongue and wait a minute or two for the relaxing effects to kick in. Applying CBD TopicallyCBD can also be applied topically in the form of creams, lotions or salves. This method is usually used to treat localised pain or inflammation, but it can also be effective for anxiety and other mental conditions. When applied to the skin, CBD interacts with cannabinoid receptors located in the body’s endocannabinoid system, which consists of the brain, nervous system and other organs. Such lotions come in many different forms and with various other ingredients that can improve the effects of cannabidiol or simply add to the experience. For example, CBD creams or salves often contain menthol or other essential oils that provide a cooling or warming sensation, which can help relieve anxiety or tension. It is worth mentioning that the effects of CBD when applied topically are not as strong or long-lasting as when inhaled or taken sublingually. Instead, the CBD in topical products is more likely to provide localised relief. Taking CBD CapsulesFinally, taking CBD in capsules is probably the most convenient way of taking cannabidiol, especially if you need to take it regularly or don’t want to mess with oils or other products. Just like CBD edibles, capsules must be ingested orally and pass through the digestive system before they take effect. However, you can know precisely how much cannabidiol you’re taking – capsules usually come in dosages from 10 mg to 100 mg and allow for easy dosing without measuring oil or adding it to food or drinks. Capsules are also a good choice if you don’t like taking oils, even though they are tasteless. You can take them just like any other pill – with water or your usual beverage. And since they don’t need to be stored at a certain temperature, as is the case with oils and other products that contain CBD, you can take them anywhere. As long as you have your bottle of capsules or container in which you store them handy, it’s easy to use cannabidiol whenever needed. What is the Optimal Dosage of CBD?The standard dosage of CBD is usually 20 – 40 mg per day, meaning that a single capsule can be enough for many people. However, it is recommended to take from 300mg to 600mg per day if your anxiety is severe. CBD affects everyone differently – what works for you might not work as well for someone else. Therefore, it is recommended to start with a smaller dosage and gradually increase it until the desired effects are achieved, just like when taking other medications. Keep in mind that you should contact your GP before taking any cannabidiol products – depending on the severity of your anxiety, it might be necessary to combine CBD with other medications. To Sum UpCBD is a popular treatment for anxiety and other conditions thanks to its anti-inflammatory, analgesic and sedative properties. It’s available in many different forms, each providing an individual experience with various effects. The most common ways of taking cannabidiol are sublingually (under the tongue), eating edibles like gummies and chocolate bars or applying topical products such as creams or lotions on your skin. However, you can also use CBD vape liquids or take capsules that contain cannabidiol oil if you don’t like tasting it or simply prefer more convenient methods of taking the product. A link to your site, with your site’s name and description as anchor text. Via https://cannatechtoday.com/5-ways-to-use-cbd-for-anxiety/ source https://renzverspaget.weebly.com/blog/5-ways-to-use-cbd-for-anxiety source https://renzverspaget.tumblr.com/post/681326161701257216 Via https://mairapostema.tumblr.com/post/681337186373763072 Every month our resident CBD and cannabis expert Ruby Deevoy answers your questions in her agony aunt column Ask Ruby. If you have a burning question about CBD or cannabis get in touch: [email protected]
Learning which form of cannabis suits your needs best is almost as important as figuring out the strains (chemovars) that work well for you. Although cannabis flower (weed) and hash are made from the same plant, they do produce different effects and a different high. While weed is simply the flowers from the cannabis plant, hash (or hashish) is concentrated, sticky resin (trichomes) from the flowers, without the actual plant matter (aside from a very small residual amount). It usually comes in a lovely, chocolatey slab or ball and has a distinct, incense-like scent. Hash was traditionally made by rubbing the flowers back and forth in the hands, but today, it’s more likely to be made using solvent extraction, dry sift or ice water extraction techniques. Both weed and hash can be smoked or vaped. Although hash is typically considered to produce a much stronger high than weed, this isn’t always the case. If the hash is made from super sticky bud, then yes, it’s likely to have concentrated levels of THC. However, it’s possible to make hash using the ‘waste product’ from a cannabis grow – the leaves or male plants – which have considerably lower levels of cannabinoids and terpenes, to begin with. This isn’t the ‘proper’ way of making hash, but as people in the UK have to buy from the illegal, unregulated market it can happen. Using up parts of the grow that would ordinarily be thrown away is obviously much more lucrative than crushing up good bud that can also be sold. The only way you can know where your hash comes from is to make your own, or be on great, trusting terms with your grower or dealer! However, high quality hash (derived from cannabis flowers) is famed for having a much higher THC content, sometimes reaching potencies of up to 60%, which is a lot compared to weed, which is generally between 15 – 30%. But one study revealed that samples of hash from Lebanon, India and Morocco only showed THC levels of up to 16%. Of course, the levels of all cannabinoids and terpenes will vary depending on the cannabis strain used in the first place. It is key to remember though, as with all things cannabis, THC content is only one very small aspect to consider. Hash also tends to have higher levels of CBD, which is usually very low in flower form. This not only lends new therapeutic benefit but can also help balance out the high that THC produces for a more ‘mellow’ effect, so the increased levels of THC may not actually be all that noticeable to a seasoned smoker. Hash is also likely to contain concentrated terpenes, which could potentially equate to increased therapeutic value. Fascinatingly, hash often contains a unique terpene, hashinene, that is produced at notable levels during the creation of this aromatic substance. Whereas all other volatile constituents of cannabis can be found in other herbs, hashinene so far appears to be entirely unique to hash. It’s thought it might be made as a result of the oxidisation of beta-myrcene (typically found in higher levels in flower and low in hash), but at this point, it remains a bit of a mystery! It’s expected that hashinene will have some unique therapeutic value to offer, but as it was only recently discovered we’ll have to wait on studies to find out what that might be. The 2014 paper in which this terpene name was coined also found that ‘samples of cannabis herb and hashish showed clear differences in their volatile chemical profile’, which as you might imagine can make the therapeutic effects quite different. Again, this will vary depending on the strain of cannabis the hash is derived from. All in all, whether you choose weed or hash is an entirely personal preference and will depend on the plants the hash you get your hands on was made from. Many people describe the experience of hash as ‘mellow’ with less anxiety, however others find it makes them feel very high! You’ll just have to give it a try and see which works best for you. from leafie https://www.leafie.co.uk/articles/ask-ruby-hash-weed-difference/ via IFTTT Via https://mairapostema.tumblr.com/post/681315657847128064 Scientists Boost THCA Yield Using New Grafting Method by Frank Schuler The cannabis plant is one of the most dynamic plants on earth, and as such, it’s also a very fun plant to cultivate. Whereas some plant varieties take a long time to grow from start to finish, the cannabis plant matures very quickly when cultivated properly. As with most crops, there are different subvarieties of the cannabis plant, often informally referred to as ‘strains.’ Different strains have different properties, with some of those properties being more or less desirable than others. The concept of differing desirability levels of properties and attributes among crop varieties is far from unique to cannabis, and cultivators of all types of crops have used a method known as ‘grafting’ over the years to combine the best attributes of multiple varieties of one or more crops. Australian StudyScientists in Australia recently grafted multiple cannabis varieties using what they described as a ‘new’ way to graft cannabis plants. “We developed a grafting methodology specifically for medicinal cannabis, involving a single step, in which a freshly cut scion is grafted to a freshly cut donor stem that will become the rootstock. This study also aimed to uncover a potential role for roots in influencing cannabinoid content,” the researchers said. “Two varieties with desirable attributes but cultivation limitations were selected to act as scions. The first, “CBD1” was a high CBDA accumulating variety with low biomass yield, and the second, “THC2”, was a high yielding, high THCA accumulating line with inconsistent root development during cloning. Two candidate rootstocks, “THC9r” and “THC8r”, were identified; both were high THCA, low CBDA varieties,” researchers said. “Our results present a new grafting method for medicinal Cannabis that improved yield in THC2 and required no additional cultivation time,” the report said. What Is THCA?For those that are new to cannabis or are not very familiar with the cannabis plant’s chemistry, the cannabis plant is comprised of dozens of cannabinoids. Two of the most popular and well-known cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD). THCA is far less known, although that is changing as time goes by. THCA stands for tetrahydrocannabinolic acid and it is the precursor to THC. As with most, if not all, cannabinoids THCA possesses wellness properties. The cannabinoid, which is the most abundant non-psychoactive cannabinoid in the cannabis plant, has been found to possess anti-inflammatory and neuroprotective properties as well as the potential to reduce nausea and vomiting. As more becomes known about THCA, global demand will increase, and that increase in demand will no doubt be met by savvy entrepreneurs that bring THCA to the marketplace in whatever manner is permitted. With that in mind, being able to boost THCA yield is a good thing, especially when considering that the scientists in Australia indicated that no additional growth time was necessary to achieve the higher THCA yield when incorporating their grafting method. This article was first published on InternationalCannabisChronicle.com. A link to your site, with your site’s name and description as anchor text. Via https://cannatechtoday.com/scientists-boost-thca-yield-using-new-grafting-method/ source https://renzverspaget.weebly.com/blog/scientists-boost-thca-yield-using-new-grafting-method source https://renzverspaget.tumblr.com/post/681269520264986624 Via https://mairapostema.tumblr.com/post/681280695586504704 Interest in psychedelics isn’t limited to inside the clinic. These drugs are going mainstream, all thanks to the increasing popularity of microdosing. With CEOs, tech gurus, and celebrities all trumpeting the benefits of this unique – albeit illegal – practice, researchers have urged users to not get ahead of the science. Many microdosers claim it to be the ultimate productivity hack: boosting mood, improving creativity, and sharpening the mind. But does it actually work? Here, we take a look at what the leading psychedelic researchers are saying about microdosing. What is microdosing?Clinical interest in psychedelic drugs is on the rise. With the practice of psychedelic-assisted psychotherapy already starting to flourish, many members of the public are keen to test the benefits themselves. A microdose, typically of LSD or psilocybin-containing ‘magic mushrooms’, is about one 10th of a standard psychedelic dose. People who microdose often choose to consume the substance two or three times a week across a two to eight week period. Since it is a sub-hallucinogenic dose, it’s too low to distort reality or trigger a significant shift in consciousness. But it is, allegedly, high enough to subtly improve emotion, cognition, and behaviour. Whilst there is a notable lack of reliable, peer-reviewed evidence in support of microdosing, positive anecdotal reports are abundant. Due to a rapidly growing online psychedelic community, the microdosing trend is gaining traction. The r/microdosing subreddit, in particular, is now nearing 200,000 members. But why are people doing it, and how has it become so popular? The perceived benefits of microdosingMicrodosing psychedelics became the trend it is now thanks to Silicon Valley, the hub of tech gurus from corporations such as Apple and Google. In what is perhaps one of the greatest case studies of microdosing, countless tech professionals turned to small doses of psychedelics to boost productivity and creativity in the workplace and, in turn, advance their careers. Psychedelic use was even endorsed by the late co-founder of Apple, Steve Jobs, who claimed that taking LSD was one of the “two or three most important things” he did in his life. As the trend swiftly spread around the globe, more and more people believe microdosing to be key to sustaining their health and wellbeing. In 2021, a large-scale survey found that adults who microdose psychedelics report having lower levels of depression, anxiety, and stress than non-microdosers. The study also revealed that the most common reasons for microdosing were to enhance mindfulness and to improve mood, creativity or learning. A similar study, published in Psychopharmacology in 2020, investigated the motivations for and perceived benefits of microdosing. Of 1,102 participants, 44% said that microdosing significantly improved their mental health, and 50% claimed that they were able to stop taking antidepressants as a result. However, due to limitations in the methodology in both of these studies, most of the evidence in favour of microdosing to improve mood and cognition is anecdotal, at best. So let’s see what the hard data is saying about the effectiveness of this practice. Has microdosing been debunked by science?In a study published in 2021, researchers from Imperial College London endeavoured to investigate how the effects of microdosing compare to a placebo drug in nearly 200 participants who were already microdosing LSD. The participants were instructed to muddle up envelopes containing either LSD or placebo capsules so that they did not know which they took. Although the results showed that microdosing did improve psychological wellbeing and life satisfaction, as did the placebo drug – and researchers found no significant differences between the effects of the two. Though, because the study involved at-home placebo control measures, the researchers acknowledge that the evidence is not as robust as a lab-based clinical study. The most reliable way of testing the effectiveness of a drug is with a double-blind placebo-controlled trial – that being, where participants are given either a treatment or a placebo drug at random, and neither they nor the researchers know who is getting which. This approach is considered to be the “gold standard” of experimental design. This particular methodology aims to compensate for participants who may expect to perceive benefits from a drug. Similarly, this also avoids any potential bias in data acquisition by the researchers. The overall results, when taken from a large sample size, provide a reliable indication of how a drug works in a particular population. To date, only a handful of double-blind placebo-controlled microdosing trials have been conducted but, again, the results aren’t hugely promising. In the most recent study, published in Addiction Biology in early 2022, participants were either given a placebo drug or 4 repeated microdoses of LSD at 3 to 4-day intervals. Researchers found that LSD “did not improve mood or affect performance on psychomotor or most emotional tasks” in comparison to the placebo. In another study, this time assessing the effectiveness of microdosing psilocybin, 75 participants self-administered either placebo or psilocybin before four laboratory sessions. The results, published in the Journal of Psychopharmacology earlier this year, showed that “microdosing with psilocybin compared to a placebo did not result in reduced depression or anxiety scores.” These results have led some scientists to believe that the microdosing craze is simply another example of the placebo effect. The power of placeboThe mind is a powerful tool; so much so, that it even holds the power to stimulate healing. This is known as the placebo effect. It is when a ‘dummy’ drug – designed to have no therapeutic benefit – appears to have an improvement on a person’s mental or physical health. In the context of microdosing, it is likely that the majority of participants of existing microdosing studies are, themselves, avid microdosers, or have a strong belief that it would help them. This, in turn, means that expectancy is likely to affect the perceived results. As explained by James Rucker, a clinician-scientist involved in psychedelic research at King’s College London, the results from recent microdosing studies suggest that “the perceived beneficial effects of microdosing psychedelics in this group are more likely to be a result of positive expectation than the capacity of the drug to induce a beneficial effect.” It is, however, important to note that the case for microdosing isn’t yet closed. “We can’t say necessarily that microdosing doesn’t work, all we can say is that, under these controlled circumstances, with this kind of participant, these doses, and these intervals, we didn’t see a robust effect,” says Harriet de Wit, lead researcher in the aforementioned LSD study. These unexpected findings are simply a call for further research. Future avenues of microdosing researchThere’s not been nearly enough research to confirm or debunk the microdosing theory. Though the recent studies cast doubts over its effectiveness, it may not be entirely placebo. In fact, one study has even shown that microdoses of LSD increase levels of brain-derived neurotrophic factor (BDNF), a protein that is highly involved in neuroplasticity and memory. Either way, there is definitely a sense of disappointment in the psychedelic community about the findings from these recent population studies. Some users claim microdosing to be a major contributor to their mental wellbeing and quality of life, so these new results have been confusing and discouraging. The truth is, there are still many things scientists are yet to uncover about psychedelics, and because of the strict Schedule 1 restrictions in the UK, their clinical investigation is hugely hindered. It may be that microdosing does something, but no one can say for certain until more research is done. In the meantime, other theories have been offered for why microdosing doesn’t appear to work. Perhaps the outcome of microdosing is dependent on the time period over which the doses are taken. Or whether the user has a diagnosed mental health condition, such as anxiety or depression. Or, perhaps, it is related to prior psychedelic use. It could be that someone who has previously experienced the psychedelic state can perceive the drug’s effects in a different way. It is, therefore, also necessary for researchers to assess the differences between experienced microdosers and those who have never used psychedelics before. For many scientists, the latest microdosing findings are hugely perplexing. It seems unlikely that these powerful hallucinogenics have zero impact on our mood and behaviour, even when used on a micro-scale. But, as it stands, that’s what the science suggests. We can only await more hard data as researchers continue to get to the bottom of the microdosing mystery. from leafie https://www.leafie.co.uk/articles/scientists-say-microdosing-might-not-work-why/ via IFTTT Via https://mairapostema.tumblr.com/post/681255247791964160 The CBD buzz has definitely made its mark on the health and wellness scene, but it looks as though this small but mighty cannabinoid is also beginning to transform the beauty industry. Countless cosmetic brands have hopped on the bandwagon, creating CBD-infused products that range from face oils to body creams to mascara. But is CBD really the ultimate beauty ally in your makeup and skincare regime? Here, we take a look at what the science says about CBD cosmetics to get to the bottom of whether they’re really worth the hype. What is CBD?Cannabidiol, better known as CBD, is one of many natural cannabinoids found in the hemp variety of the Cannabis sativa plant. It is non-psychoactive, meaning it cannot get you high. For this reason, it is widely available (and legal) to buy in the UK, and it’s proving hugely popular. CBD interacts with our endocannabinoid system (ECS), a cell signalling network that is involved in regulating our mood, appetite, sleep, immune activity, memory, and much more. It does this through the activity of cannabinoid receptors which, interestingly, can also be found in the skin barrier. The ECS is highly involved in maintaining skin health, and CBD is thought to give a helping hand with this process. There is accumulating evidence for the use of topical CBD products as a treatment for a variety of skin conditions, including acne and eczema, among others. The rise of CBD in the cosmetics industryIn the last few years, the perceived health benefits of CBD have been trumpeted far and wide. Thousands of people across the globe use this cannabinoid to help manage the symptoms of countless medical conditions and to support their everyday wellbeing. CBD is proving particularly popular for its anxiety-relieving and stress-busting properties, but could it also help to calm our skin? The CBD cosmetics industry is expanding at an extraordinary rate, with the global market predicted to grow by $2.22 billion between 2020 and 2024. The sudden interest in CBD by the beauty industry started when researchers theorised that its anti-inflammatory properties could soothe inflammatory skin conditions. Many claim topical CBD products to be effective at relieving redness, inflammation, and acne scarring. Outside of skincare, CBD is now being infused into countless cosmetic products, with the purpose of elevating our skin, hair, and makeup regimes. Belinda Carli, director at the Institute of Personal Care Science, told Cosmetics Design Europe that “CBD is an exciting area for innovation where new cosmetic uses are proven or further established with clinical efficacy.” It’s certainly a creative way to piggyback off the popularity of the cannabis industry, but how reliable is the science? Do CBD cosmetics work?Rave reviews of CBD-infused skincare products say that they can reduce redness, prevent spots, reduce scarring, and even have an anti-ageing effect on the skin. However, the clinical research is still in its very early stages and there is no conclusive evidence to support the claims that CBD is a “miracle beauty ingredient”. That being said, numerous experimental studies have shown that CBD has some pretty cool skincare credentials, so let’s take a look at how the science squares up to some of these skin-related health claims. Reduce inflammationResearch has shown that CBD, when applied to the skin, has local anti-inflammatory action. Not only has this been shown to reduce inflammatory pain, but researchers now believe that this could also minimise redness and swelling of spots, eczema, and psoriasis on the skin. Since acne is known to be an inflammatory condition, CBD products could therefore help to soothe painful breakouts and reduce the likelihood of future flare-ups. Inhibit bacteriaCutibacterium acnes is an important bacterium on the skin surface. When our skin bacteria becomes imbalanced, C. acnes can accumulate in hair follicles and potentially cause spots or acne. Numerous studies have shown that CBD has antimicrobial properties and, recently, one study found that it can specifically inhibit C. acnes, with little potential for antibiotic resistance, which is also thought to underlie some of the spot-busting properties of CBD skincare. Prevent clogged poresAttached to hair follicles are sebaceous glands, which produce an oily wax-like substance called sebum that acts as a skin barrier, protecting, hydrating, and waterproofing the face. The primary cause of acne is the overproduction of sebum. Too much sebum can clog our pores, forming blackheads, whiteheads, or even cystic breakouts. In a study of CBD on human sebaceous gland cells, CBD administration was highly sebostatic, meaning it inhibited the production of sebum. These findings are yet to be replicated in human trials so, although CBD could minimise the clogging of pores and prevent spots, there isn’t quite enough evidence to say it will. Reduce scarringResearchers can’t say for certain whether CBD can treat acne scars, but there is some evidence to suggest that CBD can encourage wound healing. In a 3-month trial of twice-daily CBD ointment application on 20 patients with skin disorders, CBD appeared to reduce scarring. Future trials with a more rigorous methodology are needed, but this is definitely an indication that topical CBD products could help to support the healing of blemishes and scars. Popular CBD-infused cosmeticsWith CBD beauty products now stocked at some of the leading online and high-street retailers, there has never been a better time to give cannabinoids a try. Here are just a few of the many types of CBD cosmetics available. CBD skincareOne of the more common ways to apply CBD to the skin is with CBD-infused face oils, creams and serums. Not only are they super hydrating, but they’re a convenient way to get a higher dose of CBD to the skin and really feel its beauty benefits. For more targeted treatment, it is also possible to buy CBD spot patches and ointments that are applied directly to the problem area. This is ideal for those with sensitive or acne-prone skin. CBD body careSkincare isn’t solely for the face. If you’re keen to try a product that soothes body acne too, you could opt for a CBD body butter or moisturiser, or perhaps a CBD-infused soap. Your options are far from limited. Or, try adding some CBD products to your self-care routine, such as bath bombs or bath soaks – and why not apply a CBD facemask while you’re at it! This way, you’re also getting to experience CBD’s stress-busting action with products that soothe both the inside and outside. CBD haircareHair products are some of the newer CBD cosmetics on the market. They are aimed to nourish the scalp, soothe itching and irritation, and promote hair growth by boosting collagen production. The evidence to support these claims is limited; CBD-infused hair products may help to hydrate and soothe the scalp and hair, but until we have hard scientific data in front of us, we can’t say for sure how effective they actually are. CBD makeupCBD and makeup may not seem like the obvious pairing, but this cannabinoid has already revolutionised the beauty space through the development of CBD makeup products. CBD-infused primers, in particular, are proving to be hugely popular, acting as a soothing and protective base for your makeup. Even decorative cosmetics, such as CBD lip products or CBD mascara, are available to buy from online beauty retailers to add a little hydrating kick to our favourite makeup products. Keen to try?With the rise of commercial CBD products, it’s clear that some brands are hopping on the cannabinoid trend without much consideration of the science. As a result, many products contain significantly less CBD than the dose used in scientific research or hardly any CBD at all. To ensure that your skin is getting enough of the good stuff to reap the benefits, look for higher potency products. Anything over 10 mg of CBD per mL should be strong enough to do the trick. As a consumer, it’s crucial that you’re buying from a legitimate and trustworthy brand. With the growing popularity of CBD, more and more people are falling victim to scams or low-quality products. At leafie, we would advise you to really do your research when looking for a new CBD cosmetic product. As well as potency, brand transparency and product traceability are key when it comes to buying CBD. Since the hemp plant accumulates much of its surrounding environment, including pesticides and toxins, a brand should disclose exactly where its CBD was grown. If this information is nowhere to be found, it’s a major red flag. Far more research is needed to assess the effectiveness of CBD-infused beauty products and to determine any potential risks or side effects. The reviews and testimonials are there, but it seems as though CBD cosmetics marketing is outpacing the science. That being said, seeing hemp-based products on the shelves is a great step forward in shaking off the stigma attached to cannabis, so it’s hugely promising in that respect. For any skincare or makeup lovers, CBD cosmetics are certainly an exciting and creative option. If you’re keen to elevate your beauty routine, it’s definitely worth giving high-quality and CBD-rich products a go to get that cannabinoid glow! from leafie https://www.leafie.co.uk/articles/cbd-taking-cosmetics-by-storm/ via IFTTT Via https://mairapostema.tumblr.com/post/681043879049543680 Breaking Exclusive: Another Cannabis Company Sues the DEA by Sara Brittany Somerset Attorneys representing a cannabis biopharma conglomerate and federal cannabis cultivation license applicant filed a petition in court today, citing that the Drug Enforcement Agency (DEA) is taking too long to issue a determination for its application. The petition, filed by Megan Sheehan of Sheehan and Associates in Rhode Island Federal District Court, is for a “Writ of Mandamus,” or an order from a court to an inferior government official(s) to properly fulfill their official duties or correct an abuse of discretion. The filing also contains a declaratory and injunctive relief complaint. MMJ BioPharma Cultivation (MMJBC), MMJ international Holdings (MMJIH), and MMJ BioPharma Labs (MMJBL) filed the petition via Sheehan to ask the court to direct the DEA to issue a determination regarding the status of its applications for a Schedule 1 Bulk Manufacturing Registration and Importing Registration. MMJ BioPharma Labs contends that the DEA has violated federal statutes and regulations concerning controlled substances by failing to decide on the company’s application for manufacturing. The company is further requesting “declaratory and injunctive relief” as a result of the DEA’s violation of the Administrative Procedures Act (APA) for the DEA’s “unreasonable delay in determining the outcome of its applications for registration for marihuana manufacturing and importing for clinical trials.” Previously, Dr. Sue Sisley of the Scottsdale Research institute successfully sued the DEA to obtain a federal cultivation license for medical cannabis research purposes. MMJ Biopharma Cultivation is following suit. Executives of MMJBC spoke exclusively to Cannabis and Tech Today about their frustration surrounding the DEA’s lengthy process. Dr. Elio Mariani, CEO of the MMJ triumvirate and a career pharma specialist of over 40 years, said, “We will get to the bottom of this unnecessary delay. Regrettably, we have had to take this course of action.” Mr. Duane Boise, President of the MMJ companies, insists that he has thoroughly investigated how the DEA has already issued registrations to other applicants. “Needless to say, they are not applying the same standards of approval consistently across the country,” said Boise. Boise maintains that the DEA has missed its self-imposed deadline for a determination. “I’m entirely flummoxed by the unconscionable dilatory conduct of the DEA. It constitutes nothing less of a dereliction of duty to MMJ, which has attended with excruciating detail to fulfill the requirements of the law,” said the Chairman of the Board of the trifecta of companies and practicing lawyer for over 50 years, Tim Moynahan. “That duty extends to all applicants, and it requires fundamental fairness and equal protection under the law. The denial of those principles to MMJ creates a laundry list of questionable actions on the DEA’s part, which is violative to the rights of all citizens,” Moynahan continued. Cannabis and Tech Today spoke to a representative in the DEA’s national office who refused to publicly comment when questioned why some applications were processed but not MMJBC’s. The agent suggested contacting the local field office for clarification; however, representatives for the DEA in Rhode Island and Boston could not be reached for comment. A link to your site, with your site’s name and description as anchor text. Via https://cannatechtoday.com/breaking-exclusive-another-cannabis-company-sues-the-dea/ source https://renzverspaget.weebly.com/blog/breaking-exclusive-another-cannabis-company-sues-the-dea source https://renzverspaget.tumblr.com/post/681024189533126656 Via https://mairapostema.tumblr.com/post/681038979164995584 On Wednesday (Apr 6th), seventeen of the U.S. Hemp Roundtable Board of Directors and staff members flew to D.C., where they met with multiple members of Congress, including U.S. Senate Minority Leader Mitch McConnell (R-KY), to voice their support for federal regulation of CBD, hemp business financial and other protections, and The Hemp Advancement Act. As reported by the roundtable, the “D.C. Fly-In” involved upwards of a dozen meetings (as well as some virtual meetings held this week) with approximately twenty members of congress, focusing on a number of highly important issues related to current and future hemp regulation. Chief among these issues was “the big one”—FDA regulation of CBD—which Senate Minority Leader Mitch McConnell personally discussed with U.S. Hemp Roundtable members. Other top-level directives strategized around in the additional meetings included supporting a number of hemp bills that would classify CBD as a dietary supplement (S. 1698 and H.R. 841), clarifying and improving existing Farm Bill provisions (H.R. 6645, The Hemp Advancement Act of 2022), and protecting “depository institutions” from penalty for servicing legitimate cannabis businesses (SAFE Banking Act). The general consensus by the roundtable following their polite incursion into Capitol Hill was that bi-partisan support of pro-hemp legislation is still very much alive after a long stretch of virtual meetings and letter writing. Per Roundtable president Pete Meachum, “After a too long absence from in-person meetings, yesterday was a very welcome opportunity to sit down with some of our biggest supporters on Capitol Hill to discuss strategy, and to advocate to new friends for their support of hemp’s policy agenda.” While we and most other hemp industry watchers have long learned to tamp down our expectations in these situations, we will monitor closely for more rumblings from D.C. and share developments as they unfold. via The CBD Insider https://thecbdinsider.com/news/us-hemp-roundtable-takes-to-dc-for-hemp-talks-with-sen-mcconnell/#utm_source=rss&utm_medium=rss&utm_campaign=us-hemp-roundtable-takes-to-dc-for-hemp-talks-with-sen-mcconnell source https://renzverspaget.weebly.com/blog/us-hemp-roundtable-takes-to-dc-for-hemp-talks-with-sen-mcconnell source https://renzverspaget.tumblr.com/post/681005311417565184 Via https://mairapostema.tumblr.com/post/681027639823220736 There are many reasons that people move into the CBD industry, some are attracted by the hyped-up financial potential of the purported green rush, while others have a personal motivation. Perhaps no one else in the UK has a deeper and more human connection with CBD than Jade Proudman, Global Brand Ambassador for Charlotte’s Web & Founder of Savage Cabbage. 6 years ago, dealing with a multitude of serious health issues, Jade found herself in a poor state of being. Simply existing from day to day, with no independence or lust for life. After becoming reliant on her partner for full-time care she began to beg for him to over dispense her prescribed medication, simply to drift off to sleep. Fortunately, her husband refused, and instead showed her a CNN documentary called WEED, featuring the founders of one of the oldest CBD brands, Charlotte’s Web. The program, and the power of cannabinoids resonated with Jade, leading her to contact one of the founders of the brand, Joel Stanley, asking for help. Obligingly a care package arrived from the company a few days later, and within 48 hours Jade had her first deep and meaningful conversation with her children in a very long time. Inspired, she wanted to share her story with the world. “I wanted to tell people about my experience, so armed with a duvet and a laptop I started talking on online forums about my experience,” Jade tells us. “Within two weeks I had set up a company and began retailing Charlotte’s Web products. I wanted to ensure people felt they were buying from a reliable source while building a community, where people could share experiences and knowledge”
Jade’s CBD journey began in 2016, way before the UK’s CBD boom which saw hundreds of brands and products flood the market. Thanks to a focus on quality, not quantity, her company has managed to ride the wave of over-saturation, as well as the challenges of the FSA’s Novel Food regulations. While the FSA intervention may have thinned out the competition a little, the CBD market remains crowded, but Jade believes Charlotte’s Web still manages to stand out from the rest for a number of reasons. “Charlotte’s Web is a vertically integrated company. Each process of the chain from seed to shelf is tested at least 20 times to ensure product quality and consistency. With patented genetics and a commitment to producing the best quality product for its consumers, Charlotte’s Web stands head and shoulders above other industry competitors. This is demonstrated by being the market leaders in the US CBD market (the largest in the world) for market share, brand awareness and brand loyalty.” Jade also believes the brand’s early adopter status is a strong appeal to customers. “CBD is a food ingredient which benefits our overall wellness. Not only did Charlotte’s Web pioneer the industry in which we are currently involved, but they also forever redefined the global perception around the wellness benefits of hemp. They’ve defined the standards of quality and expectations from a brand in this nascent industry. To this day, I am yet to see another brand that comes close to building such a level of brand equity through a mission-driven focus of bettering our planet and the people living upon it.” Jade has taken the Charlotte’s Web ethos of quality, consistency, and integrity to develop a UK based range of full spectrum hemp products under the brand name of Savage Cabbage that retail at an accessible price for consumers. She firmly believes that full spectrum is the future, after testing isolates and not getting the same results. After all, should the products we consume not be as naturally derived as possible, as mother nature intended? “The natural self-care movement is built upon Mother Nature, and using this to support our well-being. It seems a paradox to remove beneficial plant compounds for the sake of a consumer product when the entourage effect has been proven in numerous studies to create more synergistic wellness effects,” says Jade. “I’m not diminishing the role of CBD isolates. They have a role in any market for consumer choice and work for some people. However, consumers need to be educated about the merits of each kind of product. The benefits of the whole plant are known around the world, the inclusion of terpenes, flavonoids and how all cannabinoids work synergistically together should be celebrated.” Unsurprisingly, Jade is a wealth of both passion and information on the cannabis plant, and believes that the very presence of the endocannabinoid system, with cannabinoid specific receptors in our bodies, shows and demonstrates that we are biochemically engineered to onboard cannabinoids into our bodies. As a result, she believes that CBD and cannabinoids shouldn’t simply be lumped into the same category as vitamins and minerals. “The CBD industry is not like any other, I have seen many companies come and go, thinking they would be able to make a quick windfall and that’s not the case. So many comparisons are made between the vitamins market and CBD, but how can that be true when CBD interacts with each and every one of us differently. Similar to how a glass of wine may affect you and I differently, CBD is the same.” Instead, she believes the potential for cannabis and the way they help our body reach the state of homeostasis should be looked at with a dedicated focus. “What’s shocking is that the endocannabinoid system is one of the body’s largest nervous systems in our body, yet it still is barely covered in medical school. Why not?!” Jade says. It’s a good point, and is a conversation that merits another article altogether. from leafie https://www.leafie.co.uk/articles/jade-proudman-savage-cabbage/ via IFTTT Via https://mairapostema.tumblr.com/post/680957034515087360 New York Senator Introduces Cannabis Community Reinvestment Act by Patricia Miller Multi-state cannabis operators (MSOs) are making millions from the legalized industry. Meanwhile, many of the communities most impacted by cannabis prohibition have yet to experience an economic boost from legalization. To combat this troubling trend, New York State Democratic Senator James Sanders Jr. is introducing the Cannabis Community Reinvestment Act (CCRA). This initiative is backed by the National Cannabis Party (NCP), representatives of which will join the senator for his announcement on Thursday, April 7. The CCRA bill would require MSOs to reinvest in communities disproportionately impacted by cannabis prohibition. This might include building economic and cultural institutions in regions that have been most impacted by cannabis prohibition. Sen. Sanders feels MSOs have a responsibility to reinvest in local communities to create economic uplift for all who have suffered as a result of the war on drugs. “The war on drugs unleashed severe damage and ruined many lives — particularly in communities of color,” he said. “My bill will ensure the companies that profit the most from the legalization of cannabis will contribute part of their profits back into the communities most harmed by the war on drugs,” Sanders said. The Marijuana Regulation and Taxation Act (MRTA) became law in New York State in 2021, legalizing adult-use cannabis. The act created the Office of Cannabis Management to regulate the new industry. It was also charged with creating economic and social justice initiatives to facilitate equal access to opportunities in the cannabis sector. The CCRA bill would augment the efforts undertaken by the Office of Cannabis Management to create a more equitable industry. As supporters of the bill, the NCP advocates for national cannabis reform and is especially devoted to creating more equitable access to the plant and the economic opportunities that coincide with legalization. Sephida Artis-Mills, president and co-founder of the NCP, believes the MRTA is a crucial step in advancing access. “The power belongs to the people, and so does the plant. To control the way people choose their medicine, and overall wellness, is a civil rights issue we need to address,” Artis-Mills said. Prolific MC and cannabis advocate Redman, who co-founded the NCP, supports the mission of Sen. Sanders. “We can actually help regulate our own laws and help communities,” Redman said. A link to your site, with your site’s name and description as anchor text. Via https://cannatechtoday.com/new-york-senator-introduces-cannabis-community-reinvestment-act/ source https://renzverspaget.weebly.com/blog/new-york-senator-introduces-cannabis-community-reinvestment-act source https://renzverspaget.tumblr.com/post/680884506307264512 Via https://mairapostema.tumblr.com/post/680888012782108672 |
ABOUT MEHallo, ik ben Maira Postema, ik ben een responsieve gecertificeerde medische assistent die gedijt in het leveren van meelevende, efficiënte zorg in een snelle omgeving. Uitstekend vermogen om contact te maken met patiënten, samen te werken met zorgteams op alle niveaus en op de hoogte te blijven van alle huidige normen en best practices. Ervaren in zowel particuliere artsenpraktijken als grote medische groepsinstellingen. ArchivesNo Archives Categories |